Kardiomiopatia przerostowa – aktualny stan wiedzy Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
cze 30, 2012
Słowa kluczowe:
kardiomiopatia przerostowa, zaburzenia rytmu, nagła śmierć sercowa
##plugins.themes.bootstrap3.article.main##
Abstrakt
W artykule przedstawiono aktualny stan wiedzy na temat kardiomiopatii przerostowej. Podsumowano badania diagnostyczne mające obecnie zastosowanie w procesie diagnostycznym oraz przedstawiono schemat postępowania z chorym. Ponadto omówiono aktualne zalecenia dotyczące leczenia pacjentów z kardiomiopatią przerostową, ze szczególnym uwzględnieniem leczenia zaburzeń rytmu i zapobiegania nagłej śmierci sercowej.
Pobrania
Dane pobrania nie są jeszcze dostepne
##plugins.themes.bootstrap3.article.details##
Jak cytować
Możeńska , O. (2012). Kardiomiopatia przerostowa – aktualny stan wiedzy . Kardiologia W Praktyce, 6(1), 3-17. Pobrano z https://journalsmededu.pl/index.php/kwp/article/view/1585
Numer
Dział
Artykuły
Utwór dostępny jest na licencji Creative Commons Uznanie autorstwa – Użycie niekomercyjne – Bez utworów zależnych 4.0 Międzynarodowe.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
Bibliografia
1. Wigle E.D., Rakowski H., Kimball B.P., Williams W.G.: Hypertrophic cardiomyopathy. Clinical spectrum and treatment. Circulation 1995, 92: 1680.
2. Maron B.J.: Hypertrophic cardiomyopathy: a systematic review. JAMA 2002, 287: 1308.
3. Nishimura R.A., Holmes D.R. Jr.: Clinical practice. Hypertrophic obstructive cardiomyopathy. N. Engl. J. Med. 2004, 350: 1320.
4. Pollick C., Morgan C.D., Gilbert B.W. et al.: Muscular subaortic stenosis: the temporal relationship between systolic anterior motion of the anterior mitral leaflet and the pressure gradient. Circulation 1982, 66: 1087.
5. Gersh B.J., Maron B.J., Bonow R.O. et al.: 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011, 124: 2761.
6. Klues H.G., Schiffers A., Maron B.J.: Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients. J. Am. Coll. Cardiol. 1995, 26: 1699.
7. Maron B.J., Pelliccia A., Spirito P.: Cardiac disease in young trained athletes. Insights into methods for distinguishing athlete’s heart from structural heart disease, with particular emphasis on hypertrophic cardiomyopathy. Circulation 1995, 91: 1596.
8. Wigle E.D., Sasson Z., Henderson M.A. et al.: Hypertrophic cardiomyopathy. The importance of the site and the extent of hypertrophy. A review. Prog. Cardiovasc. Dis. 1985, 28: 1.
9. Maron M.S., Olivotto I., Zenovich A.G. et al.: Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation 2006, 114: 2232.
10. Shah J.S., Esteban M.T., Thaman R. et al.: Prevalence of exercise-induced left ventricular outflow tract obstruction in symptomatic patients with non-obstructive hypertrophic cardiomyopathy. Heart 2008, 94: 1288.
11. Kizilbash A.M., Heinle S.K., Grayburn P.A.: Spontaneous variability of left ventricular outflow tract gradient in hypertrophic obstructive cardiomyopathy. Circulation 1998, 97: 461.
12. Maron B.J., Gottdiener J.S., Arce J. et al.: Dynamic subaortic obstruction in hypertrophic cardiomyopathy: analysis by pulsed Doppler echocardiography. J. Am. Coll. Cardiol. 1985, 6: 1.
13. Panza J.A., Petrone R.K., Fananapazir L., Maron B.J.: Utility of continuous wave Doppler echocardiography in the noninvasive assessment of left ventricular outflow tract pressure gradient in patients with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 1992, 19: 91.
14. Klues H.G., Maron B.J., Dollar A.L., Roberts W.C.: Diversity of structural mitral valve alterations in hypertrophic cardiomyopathy. Circulation 1992, 85: 1651.
15. Adelman A.G., McLoughlin M.J., Marquis Y. et al.: Left ventricular cineangiographic observations in muscular subaortic stenosis. Am. J. Cardiol. 1969, 24: 689.
16. Maron B.J., Spirito P., Green K.J. et al.: Noninvasive assessment of left ventricular diastolic function by pulsed Doppler echocardiography in patients with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 1987, 10: 733.
17. Gwathmey J.K., Warren S.E., Briggs G.M. et al.: Diastolic dysfunction in hypertrophic cardiomyopathy. Effect on active force generation during systole. J. Clin. Invest. 1991, 87: 1023.
18. McMahon C.J., Nagueh S.F., Pignatelli R.H. et al.: Characterization of left ventricular diastolic function by tissue Doppler imaging and clinical status in children with hypertrophic cardiomyopathy. Circulation 2004, 109: 1756.
19. Nagueh S.F., Bachinski L.L., Meyer D. et al.: Tissue Doppler imaging consistently detects myocardial abnormalities in patients with hypertrophic cardiomyopathy and provides a novel means for an early diagnosis before and independently of hypertrophy. Circulation 2001, 104: 128.
20. Ho C.Y., Sweitzer N.K., McDonough B. et al.: Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy. Circulation 2002, 105: 2992.
21. Nagueh S.F., McFalls J., Meyer D. et al.: Tissue Doppler imaging predicts the development of hypertrophic cardiomyopathy in subjects with subclinical disease. Circulation 2003, 108: 395.
22. Okeie K., Shimizu M., Yoshio H. et al.: Left ventricular systolic dysfunction during exercise and dobutamine stress in patients with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 2000, 36: 856.
23. Jones S., Elliott P.M., Sharma S. et al.: Cardiopulmonary responses to exercise in patients with hypertrophic cardiomyopathy. Heart 1998, 80: 60.
24. Sadoul N., Prasad K., Elliott P.M. et al.: Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy. Circulation 1997, 96: 2987.
25. Frenneaux M.P., Counihan P.J., Caforio A.L. et al.: Abnormal blood pressure response during exercise in hypertrophic cardiomyopathy. Circulation 1990, 82: 1995.
26. Olivotto I., Maron B.J., Montereggi A. et al.: Prognostic value of systemic blood pressure response during exercise in a community-based patient population with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 1999, 33: 2044.
27. Counihan P.J., Frenneaux M.P., Webb D.J., McKenna W.J.: Abnormal vascular responses to supine exercise in hypertrophic cardiomyopathy. Circulation 1991, 84: 686.
28. Thaman R., Elliott P.M., Shah J.S. et al.: Reversal of inappropriate peripheral vascular responses in hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 2005, 46: 883.
29. Elliott P.M., Kaski J.C., Prasad K. et al.: Chest pain during daily life in patients with hypertrophic cardiomyopathy: an ambulatory electrocardiographic study. Eur. Heart J. 1996, 17: 1056.
30. O’Gara P.T., Bonow R.O., Maron B.J. et al.: Myocardial perfusion abnormalities in patients with hypertrophic cardiomyopathy: assessment with thallium-201 emission computed tomography. Circulation 1987, 76: 1214.
31. Lazzeroni E., Picano E., Morozzi L. et al.: Dipyridamole-induced ischemia as a prognostic marker of future adverse cardiac events in adult patients with hypertrophic cardiomyopathy. Echo Persantine Italian Cooperative (EPIC) Study Group, Subproject Hypertrophic Cardiomyopathy. Circulation 1997, 96: 4268.
32. Dilsizian V., Bonow R.O., Epstein S.E., Fananapazir L.: Myocardial ischemia detected by thallium scintigraphy is frequently related to cardiac arrest and syncope in young patients with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 1993, 22: 796.
33. Yamada M., Elliott P.M., Kaski J.C. et al.: Dipyridamole stress thallium-201 perfusion abnormalities in patients with hypertrophic cardiomyopathy. Relationship to clinical presentation and outcome. Eur. Heart J. 1998, 19: 500.
34. Sorajja P., Chareonthaitawee P., Ommen S.R. et al.: Prognostic utility of single-photon emission computed tomography in adult patients with hypertrophic cardiomyopathy. Am. Heart J. 2006, 151: 426.
35. Dissmann R., Schultheiss H.P.: Ischaemia in patients with hypertrophic cardiomyopathy – various causes and symptoms and the difficulties of ischaemia screening tests. Eur. Heart J. 1996, 17: 982.
36. Pasternac A., Noble J., Streulens Y. et al.: Pathophysiology of chest pain in patients with cardiomyopathies and normal coronary arteries. Circulation 1982, 65: 778.
37. Cannon R.O. 3rd, Rosing D.R., Maron B.J. et al.: Myocardial ischemia in patients with hypertrophic cardiomyopathy: contribution of inadequate vasodilator reserve and elevated left ventricular filling pressures. Circulation 1985, 71: 234.
38. Cannon R.O. 3rd, Schenke W.H., Maron B.J. et al.: Differences in coronary flow and myocardial metabolism at rest and during pacing between patients with obstructive and patients with nonobstructive hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 1987, 10: 53.
39. Ikeda H., Shimamatsu M., Yoshiga O. et al.: Impaired myocardial perfusion in patients with hypertrophic cardiomyopathy: assessment with digital subtraction coronary arteriography. Heart Vessels 1988, 4: 170.
40. Krams R., Kofflard M.J., Duncker D.J. et al.: Decreased coronary flow reserve in hypertrophic cardiomyopathy is related to remodeling of the coronary microcirculation. Circulation 1998, 97: 230.
41. Camici P., Chiriatti G., Lorenzoni R. et al.: Coronary vasodilation is impaired in both hypertrophied and nonhypertrophied myocardium of patients with hypertrophic cardiomyopathy: a study with nitrogen-13 ammonia and positron emission tomography. J. Am. Coll. Cardiol. 1991, 17: 879.
42. Tanaka M., Fujiwara H., Onodera T. et al.: Quantitative analysis of narrowings of intramyocardial small arteries in normal hearts, hypertensive hearts, and hearts with hypertrophic cardiomyopathy. Circulation 1987, 75: 1130.
43. Lorenzoni R., Gistri R., Cecchi F. et al.: Coronary vasodilator reserve is impaired in patients with hypertrophic cardiomyopathy and left ventricular dysfunction. Am. Heart J. 1998, 136: 972.
44. Caforio A.L., Rossi B., Risaliti R. et al.: Type 1 fiber abnormalities in skeletal muscle of patients with hypertrophic and dilated cardiomyopathy: evidence of subclinical myogenic myopathy. J. Am. Coll. Cardiol. 1989, 14: 1464.
45. Lankford E.B., Epstein N.D., Fananapazir L., Sweeney H.L.: Abnormal contractile properties of muscle fibers expressing beta-myosin heavy chain gene mutations in patients with hypertrophic cardiomyopathy. J. Clin. Invest. 1995, 95: 1409.
46. Fananapazir L., Dalakas M.C., Cyran F. et al.: Missense mutations in the beta-myosin heavy-chain gene cause central core disease in hypertrophic cardiomyopathy. Proc. Natl. Acad. Sci. USA 1993, 90: 3993.
47. Thompson C.H., Kemp G.J., Taylor D.J. et al.: Abnormal skeletal muscle bioenergetics in familial hypertrophic cardiomyopathy. Heart 1997, 78: 177.
48. Rickers C., Wilke N.M., Jerosch-Herold M. et al.: Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy. Circulation 2005, 112: 855.
49. Posma J.L., Blanksma P.K., van der Wall E.E. et al.: Assessment of quantitative hypertrophy scores in hypertrophic cardiomyopathy: magnetic resonance imaging versus echocardiography. Am. Heart J. 1996, 132: 1020.
50. Choudhury L., Mahrholdt H., Wagner A. et al.: Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 2002, 40: 2156.
51. Moon J.C., McKenna W.J., McCrohon J.A. et al.: Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J. Am. Coll. Cardiol. 2003, 41: 1561.
52. Petersen S.E., Jerosch-Herold M., Hudsmith L.E. et al.: Evidence for microvascular dysfunction in hypertrophic cardiomyopathy: new insights from multiparametric magnetic resonance imaging. Circulation 2007, 115: 2418.
53. Dong S.J., MacGregor J.H., Crawley A.P. et al.: Left ventricular wall thickness and regional systolic function in patients with hypertrophic cardiomyopathy. A three-dimensional tagged magnetic resonance imaging study. Circulation 1994, 90: 1200.
54. Kramer C.M., Reichek N., Ferrari V.A. et al.: Regional heterogeneity of function in hypertrophic cardiomyopathy. Circulation 1994, 90: 186.
55. Pennell D.J., Sechtem U.P., Higgins C.B. et al.: Clinical indications for cardiovascular magnetic resonance (CMR): Consensus Panel report. Eur. Heart J. 2004, 25: 1940.
56. Paelinck B.P., de Roos A., Bax J.J. et al.: Feasibility of tissue magnetic resonance imaging: a pilot study in comparison with tissue Doppler imaging and invasive measurement. J. Am. Coll. Cardiol. 2005, 45: 1109.
57. Germans T., Wilde A.A., Dijkmans P.A. et al.: Structural abnormalities of the inferoseptal left ventricular wall detected by cardiac magnetic resonance imaging in carriers of hypertrophic cardiomyopathy mutations. J. Am. Coll. Cardiol. 2006, 48: 2518.
58. Cecchi F., Olivotto I., Gistri R. et al.: Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N. Engl. J. Med. 2003, 349: 1027.
59. Olivotto I., Cecchi F., Gistri R. et al.: Relevance of coronary microvascular flow impairment to long-term remodeling and systolic dysfunction in hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 2006, 47: 1043.
60. Scanlon P.J., Faxon D.P., Audet A.M. et al.: ACC/AHA guidelines for coronary angiography: executive summary and recommendations. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Coronary Angiography) developed in collaboration with the Society for Cardiac Angiography and Interventions. Circulation 1999, 99: 2345.
61. Hasegawa K., Fujiwara H., Doyama K. et al.: Ventricular expression of brain natriuretic peptide in hypertrophic cardiomyopathy. Circulation 1993, 88: 372.
62. Nishigaki K., Tomita M., Kagawa K. et al.: Marked expression of plasma brain natriuretic peptide is a special feature of hypertrophic obstructive cardiomyopathy. J. Am. Coll. Cardiol. 1996, 28: 1234.
63. Fifer M.A., Vlahakes G.J.: Management of symptoms in hypertrophic cardiomyopathy. Circulation 2008, 117: 429.
64. Spirito P., Seidman C.E., McKenna W.J., Maron B.J.: The management of hypertrophic cardiomyopathy. N. Engl. J. Med. 1997, 336: 775.
65. Sherrid M.V., Pearle G., Gunsburg D.Z.: Mechanism of benefit of negative inotropes in obstructive hypertrophic cardiomyopathy. Circulation 1998, 97: 41.
66. Harrison D.C., Braunwald E., Glick G. et al.: Effects of beta-adrenergic blockade on the circulation with particular reference to observations in patients with hypertrophic subaortic stenosis. Circulation 1964, 29: 84.
67. Cohen L.S., Braunwald E.: Amelioration of angina pectoris in idiopathic hypertrophic subaortic stenosis with beta-adrenergic blockade. Circulation 1967, 35: 847.
68. Bonow R.O., Dilsizian V., Rosing D.R. et al.: Verapamil-induced improvement in left ventricular diastolic filling and increased exercise tolerance in patients with hypertrophic cardiomyopathy: short- and long-term effects. Circulation 1985, 72: 853.
69. Udelson J.E., Bonow R.O., O’Gara P.T. et al.: Verapamil prevents silent myocardial perfusion abnormalities during exercise in asymptomatic patients with hypertrophic cardiomyopathy. Circulation 1989, 79: 1052.
70. Gistri R., Cecchi F., Choudhury L. et al.: Effect of verapamil on absolute myocardial blood flow in hypertrophic cardiomyopathy. Am. J. Cardiol. 1994, 74: 363.
71. Maron B.J.: Hypertrophic cardiomyopathy: a systematic review. JAMA 2002, 287: 1308.
72. Braunwald E., Lambrew C.T., Rockoff S.D. et al.: Idiopathic hypertrophic subaortic stenosis. i. a description of the disease based upon an analysis of 64 patients. Circulation 1964, 30(suppl. 4): 3.
73. Anderson D.M., Raff G.L., Ports T.A. et al.: Hypertrophic obstructive cardiomyopathy. Effects of acute and chronic verapamil treatment on left ventricular systolic and diastolic function. Br. Heart J. 1984, 51: 523.
74. Rosing D.R., Idänpään-Heikkilä U., Maron B.J. et al.: Use of calcium-channel blocking drugs in hypertrophic cardiomyopathy. Am. J. Cardiol. 1985, 55: 185B.
75. Epstein S.E., Rosing D.R.: Verapamil: its potential for causing serious complications in patients with hypertrophic cardiomyopathy. Circulation 1981, 64: 437.
76. Nagao M., Omote S., Takizawa A., Yasue H.: Effect of diltiazem on left ventricular isovolumic relaxation time in patients with hypertrophic cardiomyopathy. Jpn Circ. J. 1983, 47: 54.
77. Basso C., Thiene G., Corrado D. et al.: Hypertrophic cardiomyopathy and sudden death in the young: pathologic evidence of myocardial ischemia. Hum. Pathol. 2000, 31: 988.
78. Moon J.C., Reed E., Sheppard M.N. et al.: The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 2004, 43: 2260.
79. Adabag A.S., Maron B.J., Appelbaum E. et al.: Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J. Am. Coll. Cardiol. 2008, 51: 1369.
80. Adabag A.S., Casey S.A., Kuskowski M.A. et al.: Spectrum and prognostic significance of arrhythmias on ambulatory Holter electrocardiogram in hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 2005, 45: 697.
81. Savage D.D., Seides S.F., Maron B.J. et al.: Prevalence of arrhythmias during 24-hour electrocardiographic monitoring and exercise testing in patients with obstructive and nonobstructive hypertrophic cardiomyopathy. Circulation 1979, 59: 866.
82. McKenna W.J., England D., Doi Y.L. et al.: Arrhythmia in hypertrophic cardiomyopathy. I: Influence on prognosis. Br. Heart J. 1981, 46: 168.
83. Maron B.J., Savage D.D., Wolfson J.K., Epstein S.E.: Prognostic significance of 24 hour ambulatory electrocardiographic monitoring in patients with hypertrophic cardiomyopathy: a prospective study. Am. J. Cardiol. 1981, 48: 252.
84. Elliott P.M., Poloniecki J., Dickie S. et al.: Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J. Am. Coll. Cardiol. 2000, 36: 2212.
85. Fananapazir L., Chang A.C., Epstein S.E., McAreavey D.: Prognostic determinants in hypertrophic cardiomyopathy. Prospective evaluation of a therapeutic strategy based on clinical, Holter, hemodynamic, and electrophysiological findings. Circulation 1992, 86: 730.
86. Cecchi F., Olivotto I., Montereggi A. et al.: Prognostic value of non-sustained ventricular tachycardia and the potential role of amiodarone treatment in hypertrophic cardiomyopathy: assessment in an unselected non-referral based patient population. Heart 1998, 79: 331.
87. Spirito P., Rapezzi C., Autore C. et al.: Prognosis of asymptomatic patients with hypertrophic cardiomyopathy and nonsustained ventricular tachycardia. Circulation 1994, 90: 2743.
88. Monserrat L., Elliott P.M., Gimeno J.R. et al.: Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. J. Am. Coll. Cardiol. 2003, 42: 873.
89. Shakespeare C.F., Keeling P.J., Slade A.K., McKenna W.J.: Arrhythmia and hypertrophic cardiomyopathy. Arch. Mal. Coeur Vaiss. 1992, 85(Spec. No 4): 31.
90. McKenna W.J., Oakley C.M., Krikler D.M., Goodwin J.F.: Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia. Br. Heart J. 1985, 53: 412.
91. McKenna W.J., Harris L., Rowland E. et al.: Amiodarone for long-term management of patients with hypertrophic cardiomyopathy. Am. J. Cardiol. 1984, 54: 802.
92. Elliott P.M., Gimeno J.R., Thaman R. et al.: Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy. Heart 2006, 92: 785.
93. Cecchi F., Olivotto I., Montereggi A. et al.: Hypertrophic cardiomyopathy in Tuscany: clinical course and outcome in an unselected regional population. J. Am. Coll. Cardiol. 1995, 26: 1529.
94. Spirito P., Chiarella F., Carratino L. et al.: Clinical course and prognosis of hypertrophic cardiomyopathy in an outpatient population. N. Engl. J. Med. 1989, 320: 749.
95. Elliott P., McKenna W.J.: Hypertrophic cardiomyopathy. Lancet 2004, 363: 1881.
96. Maron B.J., Shen W.K., Link M.S. et al.: Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N. Engl. J. Med. 2000, 342: 365.
97. Cecchi F., Maron B.J., Epstein S.E.: Long-term outcome of patients with hypertrophic cardiomyopathy successfully resuscitated after cardiac arrest. J. Am. Coll. Cardiol. 1989, 13: 1283.
98. Elliott P.M., Sharma S., Varnava A. et al.: Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 1999, 33: 1596.
99. Primo J., Geelen P., Brugada J. et al.: Hypertrophic cardiomyopathy: role of the implantable cardioverter-defibrillator. J. Am. Coll. Cardiol. 1998, 31: 1081.
100. McKenna W., Deanfield J., Faruqui A. et al.: Prognosis in hypertrophic cardiomyopathy: role of age and clinical, electrocardiographic and hemodynamic features. Am. J. Cardiol. 1981, 47: 532.
101. Maron B.J., Lipson L.C., Roberts W.C. et al.: „Malignant” hypertrophic cardiomyopathy: identification of a subgroup of families with unusually frequent premature death. Am. J. Cardiol. 1978, 41: 1133.
102. Priori S.G., Aliot E., Blomstrom-Lundqvist C. et al.: Task Force on Sudden Cardiac Death of the European Society of Cardiology. Eur. Heart J. 2001, 22: 1374.
103. Spirito P., Bellone P., Harris K.M. et al.: Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N. Engl. J. Med. 2000, 342: 1778.
104. Elliott P.M., Gimeno Blanes J.R., Mahon N.G. et al.: Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet 2001, 357: 420.
105. Sorajja P., Nishimura R.A., Ommen S.R. et al.: Use of echocardiography in patients with hypertrophic cardiomyopathy: clinical implications of massive hypertrophy. J. Am. Soc. Echocardiogr. 2006, 19: 788.
106. McMahon C.J., Nagueh S.F., Pignatelli R.H. et al.: Characterization of left ventricular diastolic function by tissue Doppler imaging and clinical status in children with hypertrophic cardiomyopathy. Circulation 2004, 109: 1756.
107. Dilsizian V., Bonow R.O., Epstein S.E., Fananapazir L.: Myocardial ischemia detected by thallium scintigraphy is frequently related to cardiac arrest and syncope in young patients with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 1993, 22: 796.
108. Yamada M., Elliott P.M., Kaski J.C. et al.: Dipyridamole stress thallium-201 perfusion abnormalities in patients with hypertrophic cardiomyopathy. Relationship to clinical presentation and outcome. Eur. Heart J. 1998, 19: 500.
109. Fananapazir L.: Advances in molecular genetics and management of hypertrophic cardiomyopathy. JAMA 1999, 281: 1746.
110. Ommen S.R., Maron B.J., Olivotto I. et al.: Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 2005, 46: 470.
111. McLeod C.J., Ommen S.R., Ackerman M.J. et al.: Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertrophic cardiomyopathy. Eur. Heart J. 2007, 28: 2583.
112. Melacini P., Maron B.J., Bobbo F. et al.: Evidence that pharmacological strategies lack efficacy for the prevention of sudden death in hypertrophic cardiomyopathy. Heart 2007, 93: 708.
113. Zipes D.P., Camm A.J., Borggrefe M. et al.: ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death-Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J. Am. Coll. Cardiol. 2006, 48: 1064.
114. Epstein A.E., DiMarco J.P., Ellenbogen K.A. et al.: ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 2008, 117: e350.
115. Spirito P., Autore C.: Management of hypertrophic cardiomyopathy. BMJ 2006, 332: 1251.
2. Maron B.J.: Hypertrophic cardiomyopathy: a systematic review. JAMA 2002, 287: 1308.
3. Nishimura R.A., Holmes D.R. Jr.: Clinical practice. Hypertrophic obstructive cardiomyopathy. N. Engl. J. Med. 2004, 350: 1320.
4. Pollick C., Morgan C.D., Gilbert B.W. et al.: Muscular subaortic stenosis: the temporal relationship between systolic anterior motion of the anterior mitral leaflet and the pressure gradient. Circulation 1982, 66: 1087.
5. Gersh B.J., Maron B.J., Bonow R.O. et al.: 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011, 124: 2761.
6. Klues H.G., Schiffers A., Maron B.J.: Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients. J. Am. Coll. Cardiol. 1995, 26: 1699.
7. Maron B.J., Pelliccia A., Spirito P.: Cardiac disease in young trained athletes. Insights into methods for distinguishing athlete’s heart from structural heart disease, with particular emphasis on hypertrophic cardiomyopathy. Circulation 1995, 91: 1596.
8. Wigle E.D., Sasson Z., Henderson M.A. et al.: Hypertrophic cardiomyopathy. The importance of the site and the extent of hypertrophy. A review. Prog. Cardiovasc. Dis. 1985, 28: 1.
9. Maron M.S., Olivotto I., Zenovich A.G. et al.: Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation 2006, 114: 2232.
10. Shah J.S., Esteban M.T., Thaman R. et al.: Prevalence of exercise-induced left ventricular outflow tract obstruction in symptomatic patients with non-obstructive hypertrophic cardiomyopathy. Heart 2008, 94: 1288.
11. Kizilbash A.M., Heinle S.K., Grayburn P.A.: Spontaneous variability of left ventricular outflow tract gradient in hypertrophic obstructive cardiomyopathy. Circulation 1998, 97: 461.
12. Maron B.J., Gottdiener J.S., Arce J. et al.: Dynamic subaortic obstruction in hypertrophic cardiomyopathy: analysis by pulsed Doppler echocardiography. J. Am. Coll. Cardiol. 1985, 6: 1.
13. Panza J.A., Petrone R.K., Fananapazir L., Maron B.J.: Utility of continuous wave Doppler echocardiography in the noninvasive assessment of left ventricular outflow tract pressure gradient in patients with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 1992, 19: 91.
14. Klues H.G., Maron B.J., Dollar A.L., Roberts W.C.: Diversity of structural mitral valve alterations in hypertrophic cardiomyopathy. Circulation 1992, 85: 1651.
15. Adelman A.G., McLoughlin M.J., Marquis Y. et al.: Left ventricular cineangiographic observations in muscular subaortic stenosis. Am. J. Cardiol. 1969, 24: 689.
16. Maron B.J., Spirito P., Green K.J. et al.: Noninvasive assessment of left ventricular diastolic function by pulsed Doppler echocardiography in patients with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 1987, 10: 733.
17. Gwathmey J.K., Warren S.E., Briggs G.M. et al.: Diastolic dysfunction in hypertrophic cardiomyopathy. Effect on active force generation during systole. J. Clin. Invest. 1991, 87: 1023.
18. McMahon C.J., Nagueh S.F., Pignatelli R.H. et al.: Characterization of left ventricular diastolic function by tissue Doppler imaging and clinical status in children with hypertrophic cardiomyopathy. Circulation 2004, 109: 1756.
19. Nagueh S.F., Bachinski L.L., Meyer D. et al.: Tissue Doppler imaging consistently detects myocardial abnormalities in patients with hypertrophic cardiomyopathy and provides a novel means for an early diagnosis before and independently of hypertrophy. Circulation 2001, 104: 128.
20. Ho C.Y., Sweitzer N.K., McDonough B. et al.: Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy. Circulation 2002, 105: 2992.
21. Nagueh S.F., McFalls J., Meyer D. et al.: Tissue Doppler imaging predicts the development of hypertrophic cardiomyopathy in subjects with subclinical disease. Circulation 2003, 108: 395.
22. Okeie K., Shimizu M., Yoshio H. et al.: Left ventricular systolic dysfunction during exercise and dobutamine stress in patients with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 2000, 36: 856.
23. Jones S., Elliott P.M., Sharma S. et al.: Cardiopulmonary responses to exercise in patients with hypertrophic cardiomyopathy. Heart 1998, 80: 60.
24. Sadoul N., Prasad K., Elliott P.M. et al.: Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy. Circulation 1997, 96: 2987.
25. Frenneaux M.P., Counihan P.J., Caforio A.L. et al.: Abnormal blood pressure response during exercise in hypertrophic cardiomyopathy. Circulation 1990, 82: 1995.
26. Olivotto I., Maron B.J., Montereggi A. et al.: Prognostic value of systemic blood pressure response during exercise in a community-based patient population with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 1999, 33: 2044.
27. Counihan P.J., Frenneaux M.P., Webb D.J., McKenna W.J.: Abnormal vascular responses to supine exercise in hypertrophic cardiomyopathy. Circulation 1991, 84: 686.
28. Thaman R., Elliott P.M., Shah J.S. et al.: Reversal of inappropriate peripheral vascular responses in hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 2005, 46: 883.
29. Elliott P.M., Kaski J.C., Prasad K. et al.: Chest pain during daily life in patients with hypertrophic cardiomyopathy: an ambulatory electrocardiographic study. Eur. Heart J. 1996, 17: 1056.
30. O’Gara P.T., Bonow R.O., Maron B.J. et al.: Myocardial perfusion abnormalities in patients with hypertrophic cardiomyopathy: assessment with thallium-201 emission computed tomography. Circulation 1987, 76: 1214.
31. Lazzeroni E., Picano E., Morozzi L. et al.: Dipyridamole-induced ischemia as a prognostic marker of future adverse cardiac events in adult patients with hypertrophic cardiomyopathy. Echo Persantine Italian Cooperative (EPIC) Study Group, Subproject Hypertrophic Cardiomyopathy. Circulation 1997, 96: 4268.
32. Dilsizian V., Bonow R.O., Epstein S.E., Fananapazir L.: Myocardial ischemia detected by thallium scintigraphy is frequently related to cardiac arrest and syncope in young patients with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 1993, 22: 796.
33. Yamada M., Elliott P.M., Kaski J.C. et al.: Dipyridamole stress thallium-201 perfusion abnormalities in patients with hypertrophic cardiomyopathy. Relationship to clinical presentation and outcome. Eur. Heart J. 1998, 19: 500.
34. Sorajja P., Chareonthaitawee P., Ommen S.R. et al.: Prognostic utility of single-photon emission computed tomography in adult patients with hypertrophic cardiomyopathy. Am. Heart J. 2006, 151: 426.
35. Dissmann R., Schultheiss H.P.: Ischaemia in patients with hypertrophic cardiomyopathy – various causes and symptoms and the difficulties of ischaemia screening tests. Eur. Heart J. 1996, 17: 982.
36. Pasternac A., Noble J., Streulens Y. et al.: Pathophysiology of chest pain in patients with cardiomyopathies and normal coronary arteries. Circulation 1982, 65: 778.
37. Cannon R.O. 3rd, Rosing D.R., Maron B.J. et al.: Myocardial ischemia in patients with hypertrophic cardiomyopathy: contribution of inadequate vasodilator reserve and elevated left ventricular filling pressures. Circulation 1985, 71: 234.
38. Cannon R.O. 3rd, Schenke W.H., Maron B.J. et al.: Differences in coronary flow and myocardial metabolism at rest and during pacing between patients with obstructive and patients with nonobstructive hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 1987, 10: 53.
39. Ikeda H., Shimamatsu M., Yoshiga O. et al.: Impaired myocardial perfusion in patients with hypertrophic cardiomyopathy: assessment with digital subtraction coronary arteriography. Heart Vessels 1988, 4: 170.
40. Krams R., Kofflard M.J., Duncker D.J. et al.: Decreased coronary flow reserve in hypertrophic cardiomyopathy is related to remodeling of the coronary microcirculation. Circulation 1998, 97: 230.
41. Camici P., Chiriatti G., Lorenzoni R. et al.: Coronary vasodilation is impaired in both hypertrophied and nonhypertrophied myocardium of patients with hypertrophic cardiomyopathy: a study with nitrogen-13 ammonia and positron emission tomography. J. Am. Coll. Cardiol. 1991, 17: 879.
42. Tanaka M., Fujiwara H., Onodera T. et al.: Quantitative analysis of narrowings of intramyocardial small arteries in normal hearts, hypertensive hearts, and hearts with hypertrophic cardiomyopathy. Circulation 1987, 75: 1130.
43. Lorenzoni R., Gistri R., Cecchi F. et al.: Coronary vasodilator reserve is impaired in patients with hypertrophic cardiomyopathy and left ventricular dysfunction. Am. Heart J. 1998, 136: 972.
44. Caforio A.L., Rossi B., Risaliti R. et al.: Type 1 fiber abnormalities in skeletal muscle of patients with hypertrophic and dilated cardiomyopathy: evidence of subclinical myogenic myopathy. J. Am. Coll. Cardiol. 1989, 14: 1464.
45. Lankford E.B., Epstein N.D., Fananapazir L., Sweeney H.L.: Abnormal contractile properties of muscle fibers expressing beta-myosin heavy chain gene mutations in patients with hypertrophic cardiomyopathy. J. Clin. Invest. 1995, 95: 1409.
46. Fananapazir L., Dalakas M.C., Cyran F. et al.: Missense mutations in the beta-myosin heavy-chain gene cause central core disease in hypertrophic cardiomyopathy. Proc. Natl. Acad. Sci. USA 1993, 90: 3993.
47. Thompson C.H., Kemp G.J., Taylor D.J. et al.: Abnormal skeletal muscle bioenergetics in familial hypertrophic cardiomyopathy. Heart 1997, 78: 177.
48. Rickers C., Wilke N.M., Jerosch-Herold M. et al.: Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy. Circulation 2005, 112: 855.
49. Posma J.L., Blanksma P.K., van der Wall E.E. et al.: Assessment of quantitative hypertrophy scores in hypertrophic cardiomyopathy: magnetic resonance imaging versus echocardiography. Am. Heart J. 1996, 132: 1020.
50. Choudhury L., Mahrholdt H., Wagner A. et al.: Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 2002, 40: 2156.
51. Moon J.C., McKenna W.J., McCrohon J.A. et al.: Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J. Am. Coll. Cardiol. 2003, 41: 1561.
52. Petersen S.E., Jerosch-Herold M., Hudsmith L.E. et al.: Evidence for microvascular dysfunction in hypertrophic cardiomyopathy: new insights from multiparametric magnetic resonance imaging. Circulation 2007, 115: 2418.
53. Dong S.J., MacGregor J.H., Crawley A.P. et al.: Left ventricular wall thickness and regional systolic function in patients with hypertrophic cardiomyopathy. A three-dimensional tagged magnetic resonance imaging study. Circulation 1994, 90: 1200.
54. Kramer C.M., Reichek N., Ferrari V.A. et al.: Regional heterogeneity of function in hypertrophic cardiomyopathy. Circulation 1994, 90: 186.
55. Pennell D.J., Sechtem U.P., Higgins C.B. et al.: Clinical indications for cardiovascular magnetic resonance (CMR): Consensus Panel report. Eur. Heart J. 2004, 25: 1940.
56. Paelinck B.P., de Roos A., Bax J.J. et al.: Feasibility of tissue magnetic resonance imaging: a pilot study in comparison with tissue Doppler imaging and invasive measurement. J. Am. Coll. Cardiol. 2005, 45: 1109.
57. Germans T., Wilde A.A., Dijkmans P.A. et al.: Structural abnormalities of the inferoseptal left ventricular wall detected by cardiac magnetic resonance imaging in carriers of hypertrophic cardiomyopathy mutations. J. Am. Coll. Cardiol. 2006, 48: 2518.
58. Cecchi F., Olivotto I., Gistri R. et al.: Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N. Engl. J. Med. 2003, 349: 1027.
59. Olivotto I., Cecchi F., Gistri R. et al.: Relevance of coronary microvascular flow impairment to long-term remodeling and systolic dysfunction in hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 2006, 47: 1043.
60. Scanlon P.J., Faxon D.P., Audet A.M. et al.: ACC/AHA guidelines for coronary angiography: executive summary and recommendations. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Coronary Angiography) developed in collaboration with the Society for Cardiac Angiography and Interventions. Circulation 1999, 99: 2345.
61. Hasegawa K., Fujiwara H., Doyama K. et al.: Ventricular expression of brain natriuretic peptide in hypertrophic cardiomyopathy. Circulation 1993, 88: 372.
62. Nishigaki K., Tomita M., Kagawa K. et al.: Marked expression of plasma brain natriuretic peptide is a special feature of hypertrophic obstructive cardiomyopathy. J. Am. Coll. Cardiol. 1996, 28: 1234.
63. Fifer M.A., Vlahakes G.J.: Management of symptoms in hypertrophic cardiomyopathy. Circulation 2008, 117: 429.
64. Spirito P., Seidman C.E., McKenna W.J., Maron B.J.: The management of hypertrophic cardiomyopathy. N. Engl. J. Med. 1997, 336: 775.
65. Sherrid M.V., Pearle G., Gunsburg D.Z.: Mechanism of benefit of negative inotropes in obstructive hypertrophic cardiomyopathy. Circulation 1998, 97: 41.
66. Harrison D.C., Braunwald E., Glick G. et al.: Effects of beta-adrenergic blockade on the circulation with particular reference to observations in patients with hypertrophic subaortic stenosis. Circulation 1964, 29: 84.
67. Cohen L.S., Braunwald E.: Amelioration of angina pectoris in idiopathic hypertrophic subaortic stenosis with beta-adrenergic blockade. Circulation 1967, 35: 847.
68. Bonow R.O., Dilsizian V., Rosing D.R. et al.: Verapamil-induced improvement in left ventricular diastolic filling and increased exercise tolerance in patients with hypertrophic cardiomyopathy: short- and long-term effects. Circulation 1985, 72: 853.
69. Udelson J.E., Bonow R.O., O’Gara P.T. et al.: Verapamil prevents silent myocardial perfusion abnormalities during exercise in asymptomatic patients with hypertrophic cardiomyopathy. Circulation 1989, 79: 1052.
70. Gistri R., Cecchi F., Choudhury L. et al.: Effect of verapamil on absolute myocardial blood flow in hypertrophic cardiomyopathy. Am. J. Cardiol. 1994, 74: 363.
71. Maron B.J.: Hypertrophic cardiomyopathy: a systematic review. JAMA 2002, 287: 1308.
72. Braunwald E., Lambrew C.T., Rockoff S.D. et al.: Idiopathic hypertrophic subaortic stenosis. i. a description of the disease based upon an analysis of 64 patients. Circulation 1964, 30(suppl. 4): 3.
73. Anderson D.M., Raff G.L., Ports T.A. et al.: Hypertrophic obstructive cardiomyopathy. Effects of acute and chronic verapamil treatment on left ventricular systolic and diastolic function. Br. Heart J. 1984, 51: 523.
74. Rosing D.R., Idänpään-Heikkilä U., Maron B.J. et al.: Use of calcium-channel blocking drugs in hypertrophic cardiomyopathy. Am. J. Cardiol. 1985, 55: 185B.
75. Epstein S.E., Rosing D.R.: Verapamil: its potential for causing serious complications in patients with hypertrophic cardiomyopathy. Circulation 1981, 64: 437.
76. Nagao M., Omote S., Takizawa A., Yasue H.: Effect of diltiazem on left ventricular isovolumic relaxation time in patients with hypertrophic cardiomyopathy. Jpn Circ. J. 1983, 47: 54.
77. Basso C., Thiene G., Corrado D. et al.: Hypertrophic cardiomyopathy and sudden death in the young: pathologic evidence of myocardial ischemia. Hum. Pathol. 2000, 31: 988.
78. Moon J.C., Reed E., Sheppard M.N. et al.: The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 2004, 43: 2260.
79. Adabag A.S., Maron B.J., Appelbaum E. et al.: Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J. Am. Coll. Cardiol. 2008, 51: 1369.
80. Adabag A.S., Casey S.A., Kuskowski M.A. et al.: Spectrum and prognostic significance of arrhythmias on ambulatory Holter electrocardiogram in hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 2005, 45: 697.
81. Savage D.D., Seides S.F., Maron B.J. et al.: Prevalence of arrhythmias during 24-hour electrocardiographic monitoring and exercise testing in patients with obstructive and nonobstructive hypertrophic cardiomyopathy. Circulation 1979, 59: 866.
82. McKenna W.J., England D., Doi Y.L. et al.: Arrhythmia in hypertrophic cardiomyopathy. I: Influence on prognosis. Br. Heart J. 1981, 46: 168.
83. Maron B.J., Savage D.D., Wolfson J.K., Epstein S.E.: Prognostic significance of 24 hour ambulatory electrocardiographic monitoring in patients with hypertrophic cardiomyopathy: a prospective study. Am. J. Cardiol. 1981, 48: 252.
84. Elliott P.M., Poloniecki J., Dickie S. et al.: Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J. Am. Coll. Cardiol. 2000, 36: 2212.
85. Fananapazir L., Chang A.C., Epstein S.E., McAreavey D.: Prognostic determinants in hypertrophic cardiomyopathy. Prospective evaluation of a therapeutic strategy based on clinical, Holter, hemodynamic, and electrophysiological findings. Circulation 1992, 86: 730.
86. Cecchi F., Olivotto I., Montereggi A. et al.: Prognostic value of non-sustained ventricular tachycardia and the potential role of amiodarone treatment in hypertrophic cardiomyopathy: assessment in an unselected non-referral based patient population. Heart 1998, 79: 331.
87. Spirito P., Rapezzi C., Autore C. et al.: Prognosis of asymptomatic patients with hypertrophic cardiomyopathy and nonsustained ventricular tachycardia. Circulation 1994, 90: 2743.
88. Monserrat L., Elliott P.M., Gimeno J.R. et al.: Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. J. Am. Coll. Cardiol. 2003, 42: 873.
89. Shakespeare C.F., Keeling P.J., Slade A.K., McKenna W.J.: Arrhythmia and hypertrophic cardiomyopathy. Arch. Mal. Coeur Vaiss. 1992, 85(Spec. No 4): 31.
90. McKenna W.J., Oakley C.M., Krikler D.M., Goodwin J.F.: Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia. Br. Heart J. 1985, 53: 412.
91. McKenna W.J., Harris L., Rowland E. et al.: Amiodarone for long-term management of patients with hypertrophic cardiomyopathy. Am. J. Cardiol. 1984, 54: 802.
92. Elliott P.M., Gimeno J.R., Thaman R. et al.: Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy. Heart 2006, 92: 785.
93. Cecchi F., Olivotto I., Montereggi A. et al.: Hypertrophic cardiomyopathy in Tuscany: clinical course and outcome in an unselected regional population. J. Am. Coll. Cardiol. 1995, 26: 1529.
94. Spirito P., Chiarella F., Carratino L. et al.: Clinical course and prognosis of hypertrophic cardiomyopathy in an outpatient population. N. Engl. J. Med. 1989, 320: 749.
95. Elliott P., McKenna W.J.: Hypertrophic cardiomyopathy. Lancet 2004, 363: 1881.
96. Maron B.J., Shen W.K., Link M.S. et al.: Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N. Engl. J. Med. 2000, 342: 365.
97. Cecchi F., Maron B.J., Epstein S.E.: Long-term outcome of patients with hypertrophic cardiomyopathy successfully resuscitated after cardiac arrest. J. Am. Coll. Cardiol. 1989, 13: 1283.
98. Elliott P.M., Sharma S., Varnava A. et al.: Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 1999, 33: 1596.
99. Primo J., Geelen P., Brugada J. et al.: Hypertrophic cardiomyopathy: role of the implantable cardioverter-defibrillator. J. Am. Coll. Cardiol. 1998, 31: 1081.
100. McKenna W., Deanfield J., Faruqui A. et al.: Prognosis in hypertrophic cardiomyopathy: role of age and clinical, electrocardiographic and hemodynamic features. Am. J. Cardiol. 1981, 47: 532.
101. Maron B.J., Lipson L.C., Roberts W.C. et al.: „Malignant” hypertrophic cardiomyopathy: identification of a subgroup of families with unusually frequent premature death. Am. J. Cardiol. 1978, 41: 1133.
102. Priori S.G., Aliot E., Blomstrom-Lundqvist C. et al.: Task Force on Sudden Cardiac Death of the European Society of Cardiology. Eur. Heart J. 2001, 22: 1374.
103. Spirito P., Bellone P., Harris K.M. et al.: Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N. Engl. J. Med. 2000, 342: 1778.
104. Elliott P.M., Gimeno Blanes J.R., Mahon N.G. et al.: Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet 2001, 357: 420.
105. Sorajja P., Nishimura R.A., Ommen S.R. et al.: Use of echocardiography in patients with hypertrophic cardiomyopathy: clinical implications of massive hypertrophy. J. Am. Soc. Echocardiogr. 2006, 19: 788.
106. McMahon C.J., Nagueh S.F., Pignatelli R.H. et al.: Characterization of left ventricular diastolic function by tissue Doppler imaging and clinical status in children with hypertrophic cardiomyopathy. Circulation 2004, 109: 1756.
107. Dilsizian V., Bonow R.O., Epstein S.E., Fananapazir L.: Myocardial ischemia detected by thallium scintigraphy is frequently related to cardiac arrest and syncope in young patients with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 1993, 22: 796.
108. Yamada M., Elliott P.M., Kaski J.C. et al.: Dipyridamole stress thallium-201 perfusion abnormalities in patients with hypertrophic cardiomyopathy. Relationship to clinical presentation and outcome. Eur. Heart J. 1998, 19: 500.
109. Fananapazir L.: Advances in molecular genetics and management of hypertrophic cardiomyopathy. JAMA 1999, 281: 1746.
110. Ommen S.R., Maron B.J., Olivotto I. et al.: Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 2005, 46: 470.
111. McLeod C.J., Ommen S.R., Ackerman M.J. et al.: Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertrophic cardiomyopathy. Eur. Heart J. 2007, 28: 2583.
112. Melacini P., Maron B.J., Bobbo F. et al.: Evidence that pharmacological strategies lack efficacy for the prevention of sudden death in hypertrophic cardiomyopathy. Heart 2007, 93: 708.
113. Zipes D.P., Camm A.J., Borggrefe M. et al.: ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death-Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J. Am. Coll. Cardiol. 2006, 48: 1064.
114. Epstein A.E., DiMarco J.P., Ellenbogen K.A. et al.: ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 2008, 117: e350.
115. Spirito P., Autore C.: Management of hypertrophic cardiomyopathy. BMJ 2006, 332: 1251.